General
Preferred name
IOXAGLIC ACID
Synonyms
Ioxaglic acid ()
IOXAGLATE SODIUM ()
IOXAGLATE MEGLUMINE ()
P-286 ()
Hexabrix 320 ()
Ioxaglate ()
MP 302 (MIXT. WITH IOXAGLATE SODIUM) ()
Meglumine ioxaglate ()
MP-302 ()
Sodium Ioxaglate ()
P&D ID
PD009261
CAS
59017-64-0
67992-58-9
59018-13-2
Tags
natural product
drug
available
Approved by
FDA
First approval
1985
Drug Status
investigational
approved
Max Phase
Phase 4
Drug indication
Diagnostic Aid (radiopaque medium)
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
ABSORPTION Following the intravascular route of injection, Ioxaglic acid is rapidly transported through the circulatory system to the kidneys.; ; The pharmacokinetics of radiopaque contrast media given by the IV route are described by a two-compartment model with a rapid alpha phase for drug distribution and a slow beta phase for the elimination of the drug[L1883]. Following the intravenous administration of 50 mL of ioxaglic acid in 10 healthy volunteers, the mean peak plasma concentration occurred at two (1-3) minutes, reaching a concentration of 2.1 (1.8-2.8) mg/mL. ; ; Approximately 50 percent of the intravenously administered dose was recovered in the urine at two hours, and 90% percent was recovered at the 24 hour time point [L1883].
PHARMACODYNAMICS This drug allows for the visualization of important organs and structures in the body. It binds to tissues, allowing the blockage of X-rays and diagnostic visualization in various soft tissues and body cavities [L1890]. ; ; The joint spaces in addition to the uterus and fallopian tubes may be visualized by the direct injection of the contrast medium into the region to be studied [L1885].
ROE Excreted unchanged in the urine [L1883]; The liver and small intestine provide the major alternate route of excretion. In patients with severe renal impairment, the excretion of this contrast medium through the gallbladder and into the small intestine sharply increases [L1885].
Compound Sets
10
ChEMBL Approved Drugs
CHEMBL1201291
CHEMBL1200743
CHEMBL1200508
ChEMBL Drugs
CHEMBL1201291
CHEMBL1200743
CHEMBL1200508
Drug Repurposing Hub
DrugBank
DB09313
DrugBank Approved Drugs
DB09313
DrugCentral
1472
DrugCentral Approved Drugs
1472
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
External IDs
48
Properties
(calculated by RDKit )
Molecular Weight
1268.57
Hydrogen Bond Acceptors
7
Hydrogen Bond Donors
6
Rotatable Bonds
10
Ring Count
2
Aromatic Ring Count
2
cLogP
3.45
TPSA
194.24
Fraction CSP3
0.25
Chiral centers
0.0
Largest ring
6.0
QED
0.2
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Indication
contrast agent
MOA
radiopaque medium
Source data